ReproCELL Incorporated (TYO:4978)
148.00
-1.00 (-0.67%)
Aug 27, 2026, 1:13 PM JST
ReproCELL Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 2,304 | 2,233 | 2,977 | 2,426 | 2,953 | 2,234 |
Other Revenue | - | - | 1 | - | - | - |
| 2,304 | 2,233 | 2,978 | 2,426 | 2,953 | 2,234 | |
Revenue Growth | -18.70% | -25.02% | 22.75% | -17.85% | 32.18% | 73.72% |
Cost of Revenue | 1,238 | 1,218 | 1,330 | 1,306 | 1,812 | 1,431 |
Gross Profit | 1,066 | 1,015 | 1,648 | 1,120 | 1,141 | 803 |
Selling, General & Admin | 1,248 | 1,222 | 1,226 | 1,129 | 984 | 895 |
Research & Development | 672 | 627 | 536 | 384 | 501 | 535 |
Amortization of Goodwill & Intangibles | 2 | 2 | 2 | 2 | 2 | 2 |
Operating Expenses | 1,946 | 1,875 | 1,779 | 1,530 | 1,497 | 1,450 |
Operating Income | -880 | -860 | -131 | -410 | -356 | -647 |
Interest & Investment Income | 96 | 87 | 67 | 51 | 88 | 9 |
Earnings From Equity Investments | -4 | -27 | -20 | -3 | -3 | -54 |
Currency Exchange Gain (Loss) | 160 | 109 | 17 | 88 | 21 | 20 |
Other Non Operating Income (Expenses) | 200 | 110 | 112 | 314 | 129 | 164 |
EBT Excluding Unusual Items | -428 | -581 | 45 | 40 | -121 | -508 |
Gain (Loss) on Sale of Investments | - | - | - | -9 | -52 | - |
Asset Writedown | -6 | -6 | - | -55 | -131 | -66 |
Other Unusual Items | - | - | - | -5 | - | - |
Pretax Income | -434 | -587 | 45 | -29 | -304 | -574 |
Income Tax Expense | 2 | 4 | -58 | 2 | 1 | 1 |
Earnings From Continuing Operations | -436 | -591 | 103 | -31 | -305 | -575 |
Net Income | -436 | -591 | 103 | -31 | -305 | -575 |
Net Income to Common | -436 | -591 | 103 | -31 | -305 | -575 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 95 | 95 | 93 | 86 | 84 | 76 |
Shares Outstanding (Diluted) | 95 | 95 | 93 | 86 | 84 | 76 |
Shares Change | 0.84% | 1.99% | 8.45% | 1.65% | 10.90% | 6.32% |
EPS (Basic) | -4.59 | -6.24 | 1.11 | -0.36 | -3.62 | -7.57 |
EPS (Diluted) | -4.59 | -6.24 | 1.11 | -0.36 | -3.62 | -7.57 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -481 | -80 | -182 | -291 | -290 |
Free Cash Flow Per Share | - | -5.08 | -0.86 | -2.13 | -3.46 | -3.82 |
Gross Margin | 46.27% | 45.45% | 55.34% | 46.17% | 38.64% | 35.94% |
Operating Margin | -38.19% | -38.51% | -4.40% | -16.90% | -12.06% | -28.96% |
Profit Margin | -18.92% | -26.47% | 3.46% | -1.28% | -10.33% | -25.74% |
Free Cash Flow Margin | - | -21.54% | -2.69% | -7.50% | -9.85% | -12.98% |
EBITDA | -799.75 | -786 | -82 | -374 | -308 | -588 |
EBITDA Margin | -34.71% | -35.20% | -2.75% | -15.42% | -10.43% | -26.32% |
D&A For EBITDA | 80.25 | 74 | 49 | 36 | 48 | 59 |
EBIT | -880 | -860 | -131 | -410 | -356 | -647 |
EBIT Margin | -38.19% | -38.51% | -4.40% | -16.90% | -12.06% | -28.96% |